ArticleBMC cancer2021

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.

Yuji Minegishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.